Sugar may be helpful for those with diabetes and obesity
BALTIMORE Researchers have found a new treatment that may be helpful in aiding those with diabetes and obesity, and it is most unusually a sugar.
The sugar is known as tagatose, which, according to published reports, is used in Europe to sweeten candy or orange juice. It is a naturally occurring version of fructose and is derived from the dairy byproduct whey. Tagatose has been shown to stop blood sugar spiking and is currently undergoing a one-year clinical trial to see if is, in fact, helpful in managing diabetes and weight-loss.
According to the American Diabetes Association, about 20.8 million people are diabetic and 9 out of 10 diabetics with Type 2 are overweight. Many researchers, such as Phillip Levin, an endocrinologist and director of diabetes center at Mercy, hope that tagatose can become a diet drug for patients experiencing obesity, one of the leading causes of diabetes. According to Levin, “Tagatose could be another tool for damage control. A lot of dealing with Type 2 diabetes is damage control.”
Other studies have shown that tagatose, if ingested before meals, would stop the rise in blood sugar, because it is absorbed poorly and therefore affects the way the sugar is stored. According to published reports, tagatose is said to be possibly the only diabetes drug that could raise good cholesterol and act as a cell-protecting antioxidant.
ScriptPro robotic dispensing adopted in two Haggen locations
BELLINGHAM, Washington Haggen Food & Pharmacy has added ScriptPro’s robotic dispensing devices to two of its stores, one in Ferndale and the other in Barkley Village, according to published reports.
The system automatically selects a prescription vial, counts tablets or capsules into the vial and labels it with patient, drug and dosing information.
“This system offers many advantages for our customers,” said Andrew Charter, vice president of pharmacy at Haggen Inc. “It is better than partially automated systems in providing accurately counted doses. Most importantly, it frees up our pharmacists to spend more time answering the questions of customers rather than counting pills or making labels.”
Eli Lilly, Sanofi-Aventis partner to market Cialis
BRDIGEWATER, N.J. Sanofi-Aventis has agreed to help Eli Lilly market its impotency drug Cialis, according to CNN. Financial terms were not disclosed.
Lilly gained full rights to the medicine at the beginning of 2007, when it bought the drug from ICOS for $2.3 billion.
Cialis had worldwide sales of $1.1 billion in 2007, compared with its main competitor Pfizer’s Viagra, which saw sales of $1.76 billion.